CheckMyRecalls

10,013 recalls · updated 20 Nov 2026

Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release…

Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release Capsules

Read the official FDA notice

Published
5 Nov 2025
Units affected
172,263 bottles
Agency
FDA
Country
United States

The hazard

CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.

Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

Duloxetine Delayed-Release Capsules, USP, 60 mg, a.) 90-count bottle (NDC: 51991-748-90), b.)1000-count bottle (NDC 51991-748-10),Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain; Dist. by: Breckenridge Pharmaceutical, Inc., Berkeley Heights, NJ 07922.

Brand / company
Breckenridge Pharmaceutical, Inc.
Codes / lots
90-count- Lot # 240721C; Exp. 02/28/2027 1000-count- Lot #230286C; Exp.02/28/2026
Distribution
U.S. Nationwide
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 5 Nov 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.